Compare CSX Corporation (CSX) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Medpace Holdings Inc — how do they compare? CSX Corporation trades at $47.26 (market cap $87.70B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: CSX Corporation is far larger — about 5.2× Medpace Holdings Inc's market cap, and CSX Corporation pays a 1.18% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and Medpace Holdings Inc for 14 Days on average.
| CSX | MEDP | |
|---|---|---|
Market Cap | $87.70B | $16.82B |
Volume | 6,980,781 | 223,093 |
Sector | Industrials | Health |
52-Week High | $53.21 | $630.19 |
52-Week Low | $33.68 | $393.42 |
Typical Hold Time | 55 Days | 14 Days |
Enterprise Value | $105.66B | $16.44B |
Dividend Yield | 1.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $47.34, up 1.13% today, with a bullish technical signal and strong institutional interest. Recent earnings beat expectations in Q1 and Q2 2026, though revenue and net income have declined since 2022. The stock is supported by a 58.69% analyst buy rating and a consensus price target of $51.00, with upcoming Q3 2026 earnings on October 21, 2026, as a key catalyst.
The outlook is positive due to pricing power in freight rail and dividend growth, but risks include declining profit margins, high debt levels, and economic sensitivity. Upside potential exists if earnings rebound, yet valuation multiples are elevated, warranting caution near-term.
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
